Search results
Showing 61 to 75 of 109 results for dexamethasone
Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Awaiting development Reference number: GID-TA11660 Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.
Discontinued Reference number: GID-TA10353
Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.
Evidence-based recommendations on using coronary artery stents in adults.
Discontinued Reference number: GID-TA10171
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.